Linked Life Data

9362003

Source:http://linkedlifedata.com/resource/pubmed/id/9362003

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
1997-12-4
pubmed:abstractText
A fifteen-year hiatus separated the availability of established AEDs and the new AEDs, after which the 1990s brought four new AEDs on the market. The new AEDs offer many alternatives that were unavailable before this decade for people with refractory epilepsy. Because AED clinical trials are usually based on efficacy in refractory patients, new drugs have an indication only for adjunctive therapy in people with poorly controlled seizures. In spite of their indication as adjunctive therapy, the new AEDs may eventually prove to be useful in monotherapy and even initial therapy of partial and secondarily generalized seizures. Although none of the new AEDs met all the criteria of an ideal AED, namely high oral bioavailability, rapid absorption, linear kinetics, negligible protein binding, long half life, renal excretion and low potential for drug interactions, they represent significant advances over the established AEDs. The only major barrier to broader use of the new AEDs appears to be cost.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
0888-0395
pubmed:author
pubmed:issnType
Print
pubmed:volume
29
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
330-5; quiz 336-7
pubmed:dateRevised
2005-11-16
pubmed:meshHeading
pubmed:year
1997
pubmed:articleTitle
Pharmacologic management of epilepsy: an update.
pubmed:affiliation
Veterans Affairs Medical Center, Seattle, Washington 98108, USA.
pubmed:publicationType
Journal Article, Review